Clinical Trials Browser

Interventional × Docetaxel × 30 days × Clear all

NCT03178552 2026-06-05

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04634877 2026-06-05

KEYNOTE-B21

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT07225946 2026-06-05

KLK2-PASenger

Phase 3 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT04895709 2026-06-04

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06463665 2026-06-04

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT07213674 2026-06-04

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT07287150 2026-06-04

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT07518147 2026-06-04

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07518173 2026-06-04

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Phase 3 Recruiting

HER2-positive Breast Cancer

NCT01810913 2026-06-03

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05062980 2026-06-03

Acclaim-2

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Phase 2/3 Active not recruiting

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06952504 2026-06-03

TroFuse-033

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04527991 2026-06-02

TROPiCS-04

Phase 3 Completed

711 enrolled 25 charts

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT04928846 2026-06-02

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05132075 2026-06-02

KontRASt-02

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06120075 2026-06-02

ARC-27

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06632327 2026-06-02

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06635824 2026-06-02

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Phase 3 Active not recruiting

Lung Neoplasms

NCT06931340 2026-06-02

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT07621601 2026-06-02

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 3 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT05633667 2026-06-01

VELOCITY-Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05676931 2026-06-01

EDGE-Lung

Phase 2 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT07291037 2026-06-01

TROPION-Lung17

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07459751 2026-06-01

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT07618624 2026-06-01

BRIDGE

Phase 2 Enrolling by invitation

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00588770 2026-05-29

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT02642042 2026-05-29

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2 Active not recruiting

60 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Terminated

190 enrolled 13 charts

Breast Neoplasms

NCT04310007 2026-05-29

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06863272 2026-05-29

IDeate-Prostate02

Phase 1/2 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT06881784 2026-05-29

RASolve 301

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06925737 2026-05-29

MK-2400-001

Phase 3 Recruiting

Prostatic Neoplasms

NCT07419295 2026-05-29

TroFuse-031

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT07615751 2026-05-29

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05094336 2026-05-28

MTAPESTRY 101

Phase 1/2 Active not recruiting

CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Stomach Neoplasms

NCT05836584 2026-05-28

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2 Active not recruiting

Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

NCT06123338 2026-05-28

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Phase 2 Active not recruiting

47 enrolled 16 charts

Hormone Sensitive Prostate Cancer

NCT04633252 2026-05-27

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05910827 2026-05-27

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Phase 1/2 Recruiting

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT06012435 2026-05-27

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06346392 2026-05-27

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Phase 3 Recruiting

Prostatic Neoplasms

NCT07609251 2026-05-27

A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar